RxDoctor Payments DataLook up a doctor →

Anne Hutchison

Hematology & Oncology · Columbia, SCNPI 1417068347

Payments from drug & device makers

$52,066in general payments, 2019–2025

Across 646 payments — averaging $80.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$39K
  • Novartis$1K
  • AstraZeneca$856
  • Johnson & Johnson$704
  • Pfizer$693
  • Merck$673
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,600100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.27$39,458
Novartis60$1,356
AstraZeneca(2 entities)47$856
Johnson & Johnson(2 entities)34$704
Pfizer41$693
Merck28$673
E.r. Squibb & Sons, L.L.C.39$550
Daiichi Sankyo Inc.18$454
Bristol Myers Squibb25$450
Takeda Pharmaceuticals U.S.A., Inc.26$449
AbbVie16$331
Astellas Pharma US Inc17$316
Heron Therapeutics, Inc.2$282
Sanofi11$281
Lilly USA, LLC13$271
Genentech USA, Inc.15$242
Gilead10$186
GSK8$177
Bayer9$167
EMD Serono, Inc.8$162
Ipsen Biopharmaceuticals, Inc7$159
Karyopharm Therapeutics Inc.9$157
Regeneron Healthcare Solutions, Inc.7$157
Rigel Pharmaceuticals, Inc.7$155
Octapharma USA, Inc.1$152
Sirtex Medical Inc1$149
Taiho Oncology, Inc.7$148
Puma Biotechnology, Inc.8$145
Jazz Pharmaceuticals Inc.9$143
Seagen Inc.9$142
Exelixis Inc.9$132
Incyte Corporation6$128
Amgen7$127
Spectrum Pharmaceuticals Inc.6$124
Deciphera Pharmaceuticals Inc.4$118
Array Biopharma Inc8$118
Servier Pharmaceuticals LLC5$118
Sumitomo Pharma America, Inc.6$118
Boehringer Ingelheim5$117
AVEO Pharmaceuticals, Inc.5$100
Genmab U.S., Inc.4$96
ADC Therapeutics America, Inc.5$94
Eisai Inc.4$92
Stemline Therapeutics Inc.3$75
Kyowa Kirin, Inc.5$75
G1 Therapeutics, Inc.2$63
CTI Biopharma Corp.4$61
Beone Medicines USA, Inc.3$60
Mirati Therapeutics, Inc.3$56
Pharmaessentia USA Corporation2$53
Beigene USA, Inc.3$52
Sobi, Inc3$51
Eagle Pharmaceuticals, Inc.3$50
Immunocore Limited2$48
Blueprint Medicines Corporation2$36
Aurobindo Pharma USA, Inc.2$34
Janssen Scientific Affairs, LLC1$31
Macrogenics, Inc.1$29
Adaptive Biotechnologies Corporation1$28
Pharmacyclics LLC, An Abbvie Company2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,066 in reported general payments places this provider in the 75th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$6,695,656
Medicare patients
1,484
Services billed
366,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide23$420,632
VerzenioAbemaciclib19$284,666
IbrancePalbociclib18$275,134
BrukinsaZanubrutinib14$209,139
ImbruvicaIbrutinib12$191,749
VenclextaVenetoclax13$122,750
EliquisApixaban75$44,093
XareltoRivaroxaban40$29,543
Letrozole398$11,878
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,666
Exemestane61$5,571
Anastrozole104$4,078
Tamoxifen Citrate61$2,056
Hydroxyurea28$1,408
Hydromorphone Hcl11$1,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$450$420,63223 claims
PfizerIbrance, Eliquis$693$319,22793 claims
Lilly USA, LLCVerzenio$271$284,66619 claims
Beigene USA, Inc.Brukinsa$52$209,13914 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$27$191,74912 claims
AbbVieVenclexta$331$122,75013 claims
Johnson & JohnsonXarelto$704$29,54340 claims
GSKAnoro Ellipta$177$5,66612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →